For instance, two-thirds of ERBB2-positive patients in the CRC cohort had evidence of EGFR co-amplification providing potential rationale for combining a HER2 targeted agent with cetuximab/chemotherapy in these patients. Here, ERBB2 is linked to colorectal carcinoma.